April 14, 2021 10:26 AM EDT

Amylyx to move forward with ALS program in Europe, but FDA wants another look; Humacyte adds $50M in debt financing

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Josh Sullivan

Amylyx is one of several companies looking to break through in the tough ALS field, and Wednesday they announced they’re moving forward with regulatory plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amylyx to move forward with ALS program in Europe, but FDA wants another look; Humacyte adds $50M in debt financing

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Josh Sullivan

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Amy­lyx to move for­ward with ALS pro­gram in Eu­rope, but FDA wants an­oth­er look; Hu­ma­cyte adds $50M in debt fi­nanc­ing

Editor & Founder

Senior Editor

Sign up to read this article for free.

more like this

Amylyx to move forward with ALS program in Europe, but FDA wants another look; Humacyte adds $50M in debt financing